Kandis McClure

Oct 17, 2024 | mondaq.com | Anna K. Abram |Craig B. Bleifer |Sean Feely |Kandis McClure

Recent drug pricing developments underscore that the focus on drug pricing issues is likely to continue regardless of the outcome of the upcoming November elections. CMS recently released final guidance on the Medicare Drug Price Negotiation Program and issued a Request for Information on a proposed Medicare $2 Drug List Model for comment.

Oct 16, 2024 | akingump.com | Anna K. Abram |Craig B. Bleifer |Sean Feely |Kandis McClure

Recent drug pricing developments underscore that the focus on drug pricing issues is likely to continue regardless of the outcome of the upcoming November elections. CMS recently released final guidance on the Medicare Drug Price Negotiation Program and issued a Request for Information on a proposed Medicare $2 Drug List Model for comment.

Oct 16, 2024 | lexology.com | Anna K. Abram |Craig B. Bleifer |Sean Feely |Kandis McClure

Recent drug pricing developments underscore that the focus on drug pricing issues is likely to continue regardless of the outcome of the upcoming November elections. CMS recently released final guidance on the Medicare Drug Price Negotiation Program and issued a Request for Information on a proposed Medicare $2 Drug List Model for comment.

Aug 15, 2024 | mondaq.com | Anna K. Abram |Craig B. Bleifer |Sean Feely |Kandis McClure

This week marks the second anniversary of the enactment of the Inflation Reduction Act, a partisan law that ushered in sweeping Medicare price setting reforms. The Biden-Harris Administration is poised to announce the first round of final "negotiated" drug prices, a defining milestone in IRA implementation. As IRA implementation moves forward, Constitutional challenges to the law continue to be litigated in the courts.